Contact Person

Dr. Elinor Switzer

Managing Editor

Phone: +49 (0)711 - 2 29 87 63
Fax: +49 (0)711 - 2 29 87 65
send an Email


A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity – a staphylokinase variant - An in-vivo study

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Issue: 2007: 97/6 (June) pp. 873-1060
Pages: 1037-1045

A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity – a staphylokinase variant - An in-vivo study

Janusz Szemraj 1, Adrian Stankiewicz 2, Wioletta Rozmyslowicz-Szermi¡ska 2, Andrzej Mogielnicki 3, Anna Gromotowicz 2, Wlodzimierz Buczko 3, Katarzyna Oszajca 1, Jacek Bartkowiak 1, Ewa Chabielska2
1 Department of Medical Biochemistry, Medical University of Lódˆ, Lódˆ, Poland; 2 Department of Biopharmacy and 3Department of Pharmacodynamics, Medical University of Bialystok, Bialystok, Poland


Venous thrombosis, Arterial thrombosis, Recombinant protein, antiplatelet activity, thrombolytic agent


The recombinant protein SAK-RGD-K2-Hir is characterized by its fibrin-specific properties of plasminogen activation combined with antithrombin and antiplatelet activities. It was previously shown in our in-vitro studies to be a more potent and faster-acting thrombolytic agent compared with standard r-SAK. In order to document the effects of the thrombolytic potential of SAKRGD- K2-Hir we examined this protein in an electrically induced carotid artery thrombosis model and stasis-induced venous model in rats. In the arterial thrombosis model, a bolus injection of SAK-RGD-K2-Hir was less effective than rt-PA and r-SAK. However, the most effective in the improvement and maintenance of carotid patency and in arterial thrombus mass reduction was SAK-RGD-K2. In contrast, all r-SAK derivatives reduced venous thrombus weight significantly in comparison to r-SAK and r-Hir. However, the most observable decrease in thrombus weight was obtained after application of recombinant proteins containing the r-Hir.The bleeding time was significantly prolonged in the animals treated with proteins containing r-Hir at a dose of 1.0 mg/kg.There were no observable changes in plasma fibrinogen concentration.In conclusion,our findings show thrombolytic activity in intravenous bolus injection of the novel thrombolytic agent SAK-RGD-K2-Hir in rats.Although this protein compares favourably with r-SAK in rat venous thrombolysis, we were unable to confirm the beneficial effects of SAK-RGDK2- Hir over r-SAK and rt-PA in the carotid artery thrombolysis model. Furthermore, our results also suggest that SAKRGD- K2-Hir bears a risk of bleeding, but this may be true for higher doses.

You may also be interested in...

Willem M. Lijfering 1, Michiel Coppens 2, Marlène H. W. van de Poel 1, Saskia Middeldorp 2, Karly Hamulyák 3, Ivan Bank 2, Nic J. G. M. Veeger 1, Martin H. Prins 4, Harry R. Büller 2, Jan van der Meer1

Thromb Haemost 2007 98 2: 457-563


M. L. van Montfoort (1), J. C. M. Meijers (1)

Thromb Haemost 2013 110 2: 223-232


G. Ocak (1), C. Y. Vossen (1, 2), J. I. Rotmans (3), W. M. Lijfering (1), F. R. Rosendaal (1, 4), K. J. Parlevliet (5), R. T. Krediet (6), E. W. Boeschoten (7), F. W. Dekker (1), M. Verduijn (1)

Thromb Haemost 2011 106 6: 1046-1052